###begin article-title 0
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming
###end article-title 0
###begin p 1
###xml 34 64 34 64 <email xmlns:xlink="http://www.w3.org/1999/xlink">federica.sallusto@irb.unisi.ch</email>
###xml 93 126 93 126 <email xmlns:xlink="http://www.w3.org/1999/xlink">alfonso.martin-fontecha@kcl.ac.uk</email>
CORRESPONDENCE Federica Sallusto: federica.sallusto@irb.unisi.ch OR Alfonso Martin-Fontecha: alfonso.martin-fontecha@kcl.ac.uk
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 181 182 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 205 203 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 399 401 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 635 636 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 638 640 638 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 906 908 906 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1039 1041 1039 1041 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
There is growing evidence that the maturation state of dendritic cells (DCs) is a critical parameter determining the balance between tolerance and immunity. We report that mouse CD4+ effector memory T (TEM) cells, but not naive or central memory T cells, constitutively expressed CD40L at levels sufficient to induce DC maturation in vitro and in vivo in the absence of antigenic stimulation. CD4+ TEM cells were excluded from resting lymph nodes but migrated in a CD62P-dependent fashion into reactive lymph nodes that were induced to express CD62P, in a transient or sustained fashion, on high endothelial venules. Trafficking of CD4+ TEM cells into chronic reactive lymph nodes maintained resident DCs in a mature state and promoted naive T cell responses and experimental autoimmune encephalomyelitis (EAE) to antigens administered in the absence of adjuvants. Antibodies to CD62P, which blocked CD4+ TEM cell migration into reactive lymph nodes, inhibited DC maturation, T cell priming, and induction of EAE. These results show that TEM cells can behave as endogenous adjuvants and suggest a mechanistic link between lymphocyte traffic in lymph nodes and induction of autoimmunity.
###end p 3
###begin p 4
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 216 218 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 87 90 <span type="species:ncbi:12461?0.5579302587176603|species:ncbi:42005?0.03487064116985377|species:ncbi:63330?0.02249718785151856">HEV</span>
Abbreviations used: EAE, experimental autoimmune encephalomyelitis; HA, hemagglutinin; HEV, high endothelial venule; MOG, myelin oligodendrocyte glycoprotein; PNAd, peripheral node addressin; TCM, central memory T; TEM, effector memory T.
###end p 4
###begin p 5
A. Martin-Fontecha's present address is Dept. of Nephrology and Transplantation, King's College London and Guy's and St Thomas' Hospital, SE1 9RT London, England, UK.
###end p 5
###begin p 6
G. Guarda's present address is Dept. of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
###end p 6
###begin p 7
M. Hons's present address is Theodor Kocher Institute, University of Bern, 3012 Bern, Switzerland.
###end p 7
###begin p 8
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 614 615 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1027 1028 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
DCs orchestrate a repertoire of immune responses that ranges from tolerance to self-antigens to resistance to infectious pathogens (1, 2). In lymph nodes, immature DCs continually present tissue antigens to self-reactive naive T cells, leading to abortive T cell proliferation and establishment of T cell tolerance (3-5). In contrast, mature DCs present microbial antigens and typically induce robust effector and memory T cell responses. In the latter case, DC maturation is initiated by microbial products, endogenous danger signals, or signals delivered by antigen-activated T cells, primarily through CD40L (6-8). It is generally believed that full-blown T cell immune responses are dependent on a combination of stimuli derived from microbial products, endogenous danger signals, and feedback from T cells that act in a temporally and spatially ordered fashion to induce DC maturation (9, 10). However, it has been shown in some experimental systems that the triggering of CD40, by CD40L expressed on antigen-activated CD4+ T cells or by agonistic antibodies, is sufficient to license DCs for priming of naive T cells against antigens administered in the absence of adjuvant (11-14).
###end p 8
###begin p 9
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 442 443 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
CD40L is a TNF family member that is rapidly up-regulated on antigen-activated T cells and released by activated platelets, and plays an important role in immune responses by regulating DC and B cell function (15). Several studies have reported that CD4+ effector and memory T cells contain preformed CD40L in intracellular stores that can be rapidly mobilized to the cell surface after TCR stimulation (16-18). Interestingly, mouse naive CD4+ T cells also constitutively express low amounts of CD40L, which appears to be sufficient to induce survival of autoreactive B cells in the absence of T cell activation (19). Whether circulating naive or memory T cells may influence the DC maturation state in peripheral tissues or lymph nodes through constitutive expression of CD40L remains to be established.
###end p 9
###begin p 10
###xml 81 83 81 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 360 362 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 495 496 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 498 500 498 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 523 524 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 671 673 671 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 866 867 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 869 871 865 867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1041 1043 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1045 1047 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
Under steady-state conditions, migration of naive T cells and central memory T (TCM) cells to peripheral lymph nodes is dependent on the expression of CD62L and CCR7, which mediate interaction with the cognate ligands peripheral node addressin (PNAd) and CCL21, respectively, expressed on high endothelial venules (HEVs) (20). Effector and effector memory T (TEM) cells, which lack CD62L and CCR7, are largely excluded from resting lymph nodes (21-23). However, we recently demonstrated that CD8+ TEM cells, as well as CCR7- NK cells, can efficiently migrate into lymph node draining sites of injection of mature DCs or adjuvants (24, 25). In reactive lymph nodes, CD8+ TEM and NK cells modulate ongoing responses by killing antigen-bearing DCs, thus limiting secondary immune responses, or by producing IFN-gamma, which enhances Th1 polarization. Recruitment of CD8+ TEM and NK cells is dependent on the expression of CXCR3 on migrating cells and coincides with a transient expression of its ligand, CXCL9, on HEVs of reactive lymph nodes (24, 25).
###end p 10
###begin p 11
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 72 74 72 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 272 274 272 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 579 581 579 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
In this paper, we report that mouse CD4+ TEM cells, but not naive T or TCM cells, constitutively expressed CD40L at levels sufficient to trigger phenotypic maturation of DCs and license them for priming of naive CD4+ T cells in vitro and in vivo. We also found that CD4+ TEM cells were largely excluded from resting lymph nodes but migrated in a CD62P-dependent fashion into reactive lymph nodes that were induced to express, in a transient (acute) or sustained (chronic) fashion, CD62P on HEVs. Strikingly, presentation of myelin oligodendrocyte glycoprotein (MOG) peptides by TEM cell-licensed DCs in chronic reactive lymph nodes was sufficient to prime self-reactive T cells, leading to experimental autoimmune encephalomyelitis (EAE).
###end p 11
###begin title 12
RESULTS
###end title 12
###begin title 13
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
CD4+ TEM cells constitutively express CD40L and trigger DC maturation
###end title 13
###begin p 14
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 533 534 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 554 557 554 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 577 579 577 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 591 595 591 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 602 603 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 619 621 619 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 633 637 633 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 644 645 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 652 653 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 773 775 773 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 867 875 867 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 a</xref>
###xml 894 895 894 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 897 899 897 899 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1018 1020 1018 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1028 1036 1028 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 a</xref>
###xml 1148 1150 1148 1150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1273 1275 1261 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1283 1291 1271 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 b</xref>
###xml 1331 1333 1319 1321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1369 1371 1357 1359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1461 1463 1449 1451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1469 1471 1457 1459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1751 1753 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1754 1756 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 364 367 <span type="species:ncbi:31658">CFA</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
###xml 1727 1732 <span type="species:ncbi:9606">human</span>
###xml 1737 1742 <span type="species:ncbi:10090">mouse</span>
It has been recently reported that naive CD4+ T cells constitutively express CD40L in amounts that are sufficient to promote autoreactive B cell survival (19). We asked whether constitutive expression of CD40L on naive and memory T cell subsets would be sufficient to induce DC maturation. To generate memory T cells, BALB/c mice were either immunized with KLH in CFA or were adoptively transferred with OVA-specific DO11.10 TCR transgenic naive T cells and immunized with OVA-pulsed mature DCs. At least 4 wk after immunization, CD4+ naive T cells (CD44low, CD62L+, CD127+), TCM cells (CD44high, CD62L+, CD127+), and TEM cells (CD44high, CD62L-, CD127+) were isolated from spleens of BALB/c mice (Fig. S1, available at ) and stained with antibodies to CD40L. Naive T and TCM cells isolated from KLH-immunized mice did not express detectable levels of surface CD40L (Fig. 1 a). In contrast, CD4+ TEM cells homogeneously expressed low amounts of surface CD40L, which was significantly higher compared with naive T and TCM cells (Fig. 1 a). Upon in vitro stimulation with CD3 antibodies, CD40L expression increased in all three subsets, although in TEM cells the kinetics were more rapid and the plateau level was approximately10-fold higher than that reached by naive T or TCM cells (Fig. 1 b). CD40L was also expressed on DO11.10 TEM cells but not on DO11.10 naive or TCM cells (unpublished data). CD40L mRNA was found to be expressed in comparable amounts in TCM and TEM cells (unpublished data), suggesting that the difference in protein expression may be caused by differences in translation and/or storage. Consistent with this possibility, previous studies showed the presence of prestored CD40L in memory T cells of both human and mouse origin (16-19).
###end p 14
###begin p 15
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD4<sup>+</sup> T<sub>EM</sub> cells constitutively express CD40L and promote DC maturation in vitro through CD40L&#8211;CD40 interaction.</bold>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 192 193 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 197 199 197 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 205 209 205 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 229 231 229 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 237 241 237 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 541 542 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 570 572 568 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 581 583 579 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 597 599 595 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 628 630 626 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 890 891 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1115 1118 1113 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1172 1173 1170 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1175 1177 1173 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
CD4+ TEM cells constitutively express CD40L and promote DC maturation in vitro through CD40L-CD40 interaction. (a) Surface expression of CD40L (black lines) in CD4+ T naive (CD44lowCD62L+CD127+), TCM (CD44highCD62L+CD127+), and TEM (CD44highCD62L-CD127+) cells. Gray lines represent control staining with isotype-matched control antibodies. (b) Kinetics of CD40L surface expression on CD4+ T cell subsets sorted as in panel a and stimulated in vitro with anti-CD3 and PdBU. Data are the means +/- SD of three separate experiments. Student's t test on values at time 0: TEM versus TCM, P = 0.041; TEM versus T naive, P = 0.023; TCM versus T naive, NS. Unstimulated T cells cultured for the same time had a level of CD40L expression comparable to time 0 (not depicted). (c) Expression of CD40, CD86, and MHC class II (black lines) on DCs that had been cultured for 12 h with the indicated CD4+ T cell subsets or stimulated with LPS. Gray lines represent staining of untreated immature DCs. Results are representative of four independent experiments. (d) Expression of CD86 (black lines) in wild-type DCs (top) or CD40-/- DCs (bottom) cultured for 12 h with live or fixed CD4+ TEM cells or with LPS as control. Gray lines represent staining of untreated immature DCs. Results are representative of three independent experiments.
###end p 15
###begin p 16
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 24 26 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 183 185 183 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 223 225 223 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 344 352 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 c</xref>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 418 420 418 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 575 577 575 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 617 620 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 626 634 626 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 d</xref>
###xml 785 786 785 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 788 790 788 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 818 820 818 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 776 781 <span type="species:ncbi:10090">mouse</span>
CD4+ naive T, TCM, and TEM cells were then cultured with syngeneic immature BM-derived DCs, and the expression of DC activation markers was measured after 24 h. Although naive T and TCM cells did not induce DC maturation, TEM cells induced up-regulation of CD40, CD86, and MHC class II molecules to an extent comparable to that induced by LPS (Fig. 1 c). DC maturation was also triggered by glutaraldehyde-fixed CD4+ TEM cells (Fig. 1 d, top), indicating that the latter trigger DC maturation in the absence of antigen-dependent or -independent signaling. In addition, CD4+ TEM cells did not induce maturation of CD40-/- DCs (Fig. 1 d, bottom), indicating that the maturation signal is delivered to DCs through a CD40-CD40L interaction. Collectively, these data indicate that mouse CD4+ TEM cells, but not naive T or TCM cells, constitutively expressed CD40L at levels sufficient to trigger in vitro phenotypic maturation of DCs.
###end p 16
###begin title 17
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
CD4+ TEM cell-matured DCs prime naive T cells in vitro
###end title 17
###begin p 18
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 248 250 248 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 257 259 257 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 440 448 440 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 a</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 739 741 735 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 768 770 764 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 778 786 774 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 a</xref>
###xml 846 847 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 947 948 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 950 952 946 948 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 979 981 975 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 989 997 985 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 b</xref>
###xml 1042 1043 1038 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1045 1047 1041 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1071 1072 1067 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1162 1165 1158 1161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1171 1179 1167 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 c</xref>
###xml 1241 1242 1237 1238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1244 1246 1240 1242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1398 1399 1394 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1401 1403 1397 1399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
We next asked whether TEM cell-matured DCs would be capable of priming naive T cells. Hemagglutinin (HA) peptide-pulsed immature DCs were cultured with CFSE-labeled HA-specific 6.5 TCR transgenic CD4+ naive T cells alone or together with naive T, TCM, and TEM cells specific for a different antigen (DO11.10 TCR transgenic T cells recognizing OVA). HA-specific naive T cells did not proliferate when stimulated with HA-pulsed immature DCs (Fig. 2 a), consistent with the notion that immature DCs have poor co-stimulatory capacity and fail to prime naive T cells (26). However, these cells proliferated vigorously and differentiated to IFN-gamma-producing effector T cells when stimulated with immature DCs in the presence of OVA-specific TEM cells but not naive T or TCM cells (Fig. 2 a and not depicted). Similarly, CFSE-labeled OVA-specific CD4+ naive T cells proliferated in response to OVA-pulsed immature DCs when cultured with polyclonal CD4+ TEM cells but not naive T or TCM cells (Fig. 2 b). Finally, in the presence of polyclonal CD4+ TEM cells, OVA-specific CD4+ naive T cells proliferated in response to OVA peptide presented by wild-type but not CD40-/- DCs (Fig. 2 c). The results of these in vitro experiments indicate that CD4+ TEM cells can license immature DCs for priming of naive T cells in an antigen-independent and CD40-dependent fashion, and raise the question of whether CD4+ TEM cells might induce DC maturation in vivo.
###end p 18
###begin p 19
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 13 15 13 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD40L<sup>+</sup> CD4<sup>+</sup> T<sub>EM</sub> cells license DCs for T cell priming in vitro.</bold>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 166 173 165 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">110-119</sub>
###xml 286 287 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 300 297 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 306 308 305 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 389 390 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 424 431 422 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 530 532 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 538 540 536 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 621 622 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 657 659 655 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 713 716 711 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
CD40L+ CD4+ TEM cells license DCs for T cell priming in vitro. (a) Proliferation of CFSE-labeled HA-specific 6.5 transgenic naive CD4+ T cells cultured with 50 muM HA110-119-pulsed syngeneic immature DCs in the absence or presence of ex vivo-isolated OVA-specific DO11.10 transgenic CD4+ T naive, TCM, or TEM cells. (b) Proliferation of CFSE-labeled OVA-specific OT-II transgenic naive CD4+ T cells cultured with 0.1 muM OVA323-339-pulsed syngeneic immature DCs in the absence or presence of ex vivo-isolated polyclonal T naive, TCM, or TEM cells. (c) Proliferation of CFSE-labeled OVA-specific OT-II transgenic naive CD4+ T cells cultured with polyclonal TEM cells in the presence of OVA-pulsed wild-type or CD40-/- immature DCs. Shown is the CFSE profile of T cells measured on day 5. Results are representative of at least three independent experiments.
###end p 19
###begin title 20
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
CD4+ TEM cells rapidly migrate into reactive lymph nodes in a CD62P-dependent, CXCR3-independent fashion
###end title 20
###begin p 21
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 286 288 286 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 326 327 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 329 331 329 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 535 537 535 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 674 676 674 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 683 684 683 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 697 699 697 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 706 707 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 902 910 902 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 a</xref>
###xml 927 929 927 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1116 1118 1116 1118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1354 1362 1354 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 a</xref>
###xml 1378 1380 1378 1380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1466 1474 1466 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 b</xref>
###xml 1617 1619 1617 1619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
Mouse CD4+ and CD8+ TEM cells lack CCR7 and CD62L and are therefore largely excluded from lymph nodes in the steady state (21-23). However, it is increasingly recognized that lymph nodes undergoing an immune response show an increased cellularity and become capable of recruiting CD8+ TEM and NK cells (27). Recruitment of CD8+ TEM and NK cells is dependent on expression of CXCR3 on migrating cells and coincides with a transient expression of its ligand, CXCL9, on HEVs of reactive lymph nodes (24, 25). To investigate whether CD4+ TEM cells would be also recruited to reactive lymph nodes, we injected i.v. in vivo-generated OVA-specific memory T cells, comprising both TCM (CD127+CD62L+) and TEM (CD127+CD62L-) cells, into syngeneic mice and measured their migration into a reactive lymph node, which had been induced by s.c. injection of LPS-matured DCs, and into a resting lymph node as control (Fig. 3 a). As expected, TCM cells, which represented a minor fraction of the transferred cell population, were highly enriched in resting lymph nodes, accounting for up to 90% of the recruited cells. In contrast, TEM cells were virtually excluded from resting lymph nodes but efficiently migrated into reactive lymph nodes, where they accounted for up to 85% of the migrated cells, a figure similar to that found in the spleen and inflamed peritoneum (Fig. 3 a). Transferred TEM cells were detected in reactive lymph nodes as early as 20 min after i.v. injection (Fig. 3 b), consistent with a direct migration of circulating T cells through HEVs rather than transit from tissues. In addition, 16 h after transfer, TEM cells colocalized with naive T cells in the T cell areas of reactive lymph nodes (Fig. S2, available at ).
###end p 21
###begin p 22
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD4<sup>+</sup> T<sub>EM</sub> cells rapidly migrate to reactive lymph nodes in a CD62P-dependent, CXCR3-independent manner.</bold>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 350 351 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 621 622 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 624 626 624 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 632 633 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 639 640 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 645 646 645 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 651 652 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 659 661 659 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 674 675 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 680 681 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 686 687 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 836 837 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 839 841 839 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 849 850 849 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 855 856 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 861 862 861 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1006 1007 1006 1007 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1012 1013 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1015 1017 1015 1017 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1098 1100 1098 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1136 1139 1136 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1251 1252 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 1358 1359 1358 1359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1419 1420 1419 1420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1422 1424 1422 1424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1431 1432 1431 1432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1437 1438 1437 1438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1443 1444 1443 1444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1565 1566 1565 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1568 1570 1568 1570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1578 1579 1578 1579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1584 1585 1584 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1590 1591 1590 1591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1887 1888 1885 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1281 1286 <span type="species:ncbi:10090">mouse</span>
###xml 1525 1529 <span type="species:ncbi:10090">mice</span>
###xml 1626 1630 <span type="species:ncbi:10090">mice</span>
###xml 1825 1829 <span type="species:ncbi:10090">mice</span>
CD4+ TEM cells rapidly migrate to reactive lymph nodes in a CD62P-dependent, CXCR3-independent manner. Adoptively transferred TCR transgenic OVA-specific naive T cells were primed by immunization with an s.c. injection of 106 OVA-pulsed syngeneic LPS-matured DCs. 3 wk later, memory CD4+ T cells were enriched from spleens and lymph nodes, and 3 x 106 T cells were injected i.v. into mice in which reactive lymph nodes had been induced 24 h before by injection of 106 syngeneic LPS-matured DCs. Some mice received also an i.p. injection of thioglycolate 48 h before T cell transfer. (a) Relative proportion of DO11.10 CD4+ TCM (CFSE-KJ1-26+CD62L+CD127+) and TEM (CFSE-KJ1-26+CD62L-CD127+) cells in the population before transfer and in the indicated organs 12 h after transfer (percentages are shown). (b) Absolute number of DO11.10 CD4+ TEM (KJ1-26+CD62L-CD127+) cells in reactive lymph nodes of mice 20 or 60 min after T cell transfer. (c) Expression of CD62P ligands and CXCR3 (black lines) on gated CD4+CD62L- TEM cells. The gray dashed lines represent background staining. (d) Percentages of TEM-like cells from wild-type and CXCR3-/- mice in reactive lymph nodes and spleen 24 h after i.v. injection. T cells were mixed at a ratio of 1:1, and 107 cells were injected in each mouse in which a reactive lymph node was produced by s.c. injection of 3 x 106 mature DCs in the footpad. (e) Absolute number of OT-II CD4+ TEM (Ly5.1+CD62L-CD127+) cells in reactive lymph nodes of wild-type C57BL/6 or CD62P/E double-deficient mice. (f) Absolute number of DO11.10 CD4+ TEM (KJ1-26+CD62L-CD127+) cells in reactive lymph nodes of mice 12 h after injection of blocking antibodies to CD62P or CD62E or of isotype-matched control antibodies. Data are the means +/- SD of two or three independent experiments each performed with two mice per condition. p-values were obtained with the Student's t test.
###end p 22
###begin p 23
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 24 26 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 254 262 254 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 c</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 338 336 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 380 382 380 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 734 742 734 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 d</xref>
###xml 803 804 803 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 806 808 806 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 856 858 856 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1020 1028 1020 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 e</xref>
###xml 1058 1060 1058 1060 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1180 1188 1180 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 f</xref>
###xml 1251 1252 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1254 1256 1254 1256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 912 916 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
In vivo-generated CD4+ TEM cells homogeneously expressed CXCR3, the receptor for CXCL9, a chemokine expressed on HEVs of reactive lymph nodes, and P-selectin glycoprotein ligand 1, the ligand for CD62P/CD62E expressed on endothelial cells and platelets (Fig. 3 c) (28). To investigate the requirements for CXCR3 in the process of CD4+ TEM cell migration to reactive lymph nodes, TEM-like cells (96% CD62L negative) were generated in vitro from wild-type and CXCR3-deficient mice, mixed at a 1:1 ratio, and injected i.v. into mice carrying a reactive lymph node induced by s.c. injection of LPS-matured DCs. Surprisingly, wild-type and CXCR3-deficient T cells were recovered in similar proportions in spleens and reactive lymph nodes (Fig. 3 d), indicating that CXCR3 is not required for migration of CD4+ TEM cells into reactive lymph nodes. In contrast, TEM cells generated in vivo by immunization of wild-type mice and transferred into mice lacking CD62P and CD62E selectins failed to migrate to reactive lymph nodes (Fig. 3 e). Furthermore, migration of TEM cells to reactive lymph nodes of wild-type mice was inhibited by injection of antibodies blocking CD62P but not CD62E (Fig. 3 f). Collectively, these results indicate that recruitment of CD4+ TEM cells into reactive lymph nodes is dependent on CD62P expression on endothelial cells but independent of CXCR3 expression on migrating T cells.
###end p 23
###begin title 24
Transient and sustained expression of CD62P on HEVs of reactive lymph nodes
###end title 24
###begin p 25
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 a</xref>
###xml 693 701 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 a</xref>
###xml 838 846 826 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 b</xref>
###xml 1085 1093 1073 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 a</xref>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 818 821 <span type="species:ncbi:31658">CFA</span>
###xml 977 980 <span type="species:ncbi:31658">CFA</span>
We next investigated whether and under which conditions CD62P would be expressed on HEVs of lymph nodes. Reactive lymph nodes were induced by s.c. injection of either LPS-matured DCs or adjuvants. After 2 or 30 d, mice were injected i.v. with fluorescinated antibodies to CD62P to stain the luminal side of HEVs. Reactive and resting lymph nodes were collected and examined by immunohistology after counterstaining with PNAd antibodies to identify HEVs. As shown in Fig. 4 a, CD62P was not expressed on the HEVs of resting lymph nodes. After a single injection of mature DCs (DC 1x), CD62P was readily detected on day 2, persisted for approximately6 d, and was no longer detectable on day 30 (Fig. 4 a and not depicted). CD62P was also detected on HEVs of draining lymph nodes 2 d after injection of adjuvants such as CFA, CpG, LPS, IFA (Fig. 4 b), R848, and TNF (not depicted). Remarkably, however, two consecutive injections 2 d apart of DCs (DC 2x) or a single injection of CFA, but not one or two injections of CpG or LPS, led to a sustained expression of CD62P on HEVs for >30 d (Fig. 4 a and not depicted). The different staining patterns of CD62P and PNAd on HEVs may be caused by differences in cellular localization or by technical reasons, because antibodies to CD62P were injected i.v., whereas anti-PNAd antibodies were added on tissue sections.
###end p 25
###begin p 26
###xml 128 130 128 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 148 0 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of CD62P on HEVs of reactive lymph nodes correlates with increased lymph node cellularity and selective increase of T<sub>EM</sub> cell recruitment.</bold>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1027 1028 1024 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1227 1229 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1243 1245 1240 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1248 1250 1245 1247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1256 1258 1253 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1263 1264 1260 1261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1267 1269 1264 1266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1275 1277 1272 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1282 1283 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1292 1293 1289 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1299 1300 1296 1297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1310 1311 1307 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1317 1318 1314 1315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1326 1327 1323 1324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1332 1333 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1344 1345 1341 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1351 1353 1348 1350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1370 1371 1367 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1377 1379 1374 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1389 1390 1386 1387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1396 1398 1393 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1436 1438 1433 1435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1706 1707 1701 1702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 928 931 <span type="species:ncbi:31658">CFA</span>
###xml 1045 1048 <span type="species:ncbi:31658">CFA</span>
###xml 1644 1648 <span type="species:ncbi:10090">mice</span>
Expression of CD62P on HEVs of reactive lymph nodes correlates with increased lymph node cellularity and selective increase of TEM cell recruitment. (a) Reactive lymph nodes were induced by one or two consecutive (2 d apart) injections of 106 LPS-matured DCs (DC 1x and DC 2x, respectively). After 2 or 30 d, mice received an i.v. injection of 100 mug FITC-labeled anti-CD62P antibody. After 30 min, lymph nodes were collected, snap frozen, and processed for immunohistochemistry. Shown is the expression of PNAd (red) and CD62P (green) in resting and reactive lymph nodes. Bar, 100 mum. (b) CD62P expression in reactive lymph nodes detected by in vivo staining 2 d after s.c. injection of the indicated adjuvants. Results are representative of three independent experiments. Bar, 100 mum. (c) Absolute cell number in resting and reactive draining lymph nodes at different time points after s.c. injection of PBS, as control or CFA, or one or two consecutive s.c. injections of mature DCs. The asterisk indicates the Student's t test on values: CFA versus PBS, P = 0.013; DC 2x vs. PBS, P = 0.001. (d) Fold increase of the indicated cell populations in day 30 reactive lymph nodes compared with resting lymph nodes (naive, CD44lo; memory, CD44hi; TCM, CD44hiCD62L+; TEM, CD44hiCD62L-; NK, CD3- NK1.1+; NKT, CD3+ NK1.1+; B, CD3- CD19+; pDC, B220+ CD11clo; dermal DC, B220- CD11clo; LC, B220- CD11chi). (e) Absolute number of endogenous TEM cells recovered in resting and reactive lymph nodes 30 d after injection of DCs or adjuvants, as indicated. Data are the means +/- SD of two to three separate experiments, each performed with two or three mice per condition. p-values were obtained with the Student's t test.
###end p 26
###begin p 27
###xml 255 263 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 c</xref>
###xml 400 401 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 577 578 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 580 582 580 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 642 650 642 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 d</xref>
###xml 796 797 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 802 806 802 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 811 812 811 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 819 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 821 823 821 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 955 963 955 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 e</xref>
###xml 1119 1121 1119 1121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1146 1148 1146 1148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 125 128 <span type="species:ncbi:31658">CFA</span>
###xml 736 739 <span type="species:ncbi:31658">CFA</span>
The sustained expression of CD62P on HEVs of lymph nodes stimulated by two injections of mature DCs or a single injection of CFA correlated with a significant increase of lymph node cellularity that was sustained for up to 60 d after initial stimulation (Fig. 4 c and not depicted). In spite of the marked increase in total cell number, the relative proportion of different cell subsets-including CD8+ T, NK, NKT, and B cells, as well as plasmacytoid DCs, dermal DCs, and Langerhans cells-was comparable in resting and DC-reactive lymph nodes, with the only exception being CD4+ TEM cells, which were highly enriched in reactive lymph nodes (Fig. 4 d). Lymph nodes stimulated 30 d earlier with two injections of DCs or one injection of CFA contained significantly higher numbers of endogenous CD4+ CD44highCD127+ CD62L- TEM cells compared with resting lymph nodes, or lymph nodes stimulated by one injection of DCs or one or two injections of CpG or LPS (Fig. 4 e). In addition, reactive lymph nodes induced 6 or 30 d before by one or two consecutive injections of LPS-matured DCs recruited i.v.-injected OVA-specific TEM cells, indicating that TEM cell migration into reactive lymph nodes is not dependent on the presence of a specific antigen (Fig. S3 a, available at ).
###end p 27
###begin p 28
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 140 142 140 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 316 324 316 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 f</xref>
###xml 333 335 333 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 440 442 440 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 527 529 527 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 961 962 961 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 964 966 964 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 95 98 <span type="species:ncbi:31658">CFA</span>
The increased number of TEM cells found in reactive lymph nodes 30 d after injection of DCs or CFA may result from an increase in resident TEM cells or may depend on a continuous recruitment of TEM cells from the blood. To distinguish between these possibilities, we injected antibodies to CD62P, which, as shown in Fig. 3 f, block TEM cell recruitment into reactive lymph nodes. Within a few hours after antibody injection, the number of TEM cells in reactive lymph nodes decreased substantially (Fig. S3 b), indicating that TEM cells continually recirculate from blood to lymph node and from there to efferent lymph. We conclude that expression of CD62P on the luminal side of HEVs of reactive lymph nodes can be induced in a transient or sustained fashion depending on the nature of the eliciting stimulus, and coincides with increased lymph node cellularity, which was caused by a uniform increase of all major cell subsets and a much higher increase of CD4+ TEM cells.
###end p 28
###begin p 29
###xml 135 138 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 487 489 481 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 523 531 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 f</xref>
###xml 654 656 648 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 100 103 <span type="species:ncbi:31658">CFA</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
We also investigated the role of T cells in induction and maintenance of reactive lymph nodes. When CFA was injected s.c. in CD3epsilon-/- mice, cell numbers in draining lymph nodes increased on day 2, but this increase was not sustained at later time points (Fig. S4 a, available at ), suggesting that T cells may be required for the establishment and/or maintenance of chronic reactive lymph nodes. When wild-type mice were injected with antibodies to CD62P that prevent migration of TEM cells into reactive lymph nodes (Fig. 3 f), the increase in lymph node cellularity was almost entirely prevented (Fig. S4 b), consistent with the possibility that TEM cells migrating in a CD62P-dependent fashion are required for long-term maintenance of chronic reactive lymph nodes.
###end p 29
###begin title 30
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
CD4+ TEM cells in lymph node license DCs for T cell priming
###end title 30
###begin p 31
###xml 58 60 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 469 467 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 533 541 533 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 a</xref>
###xml 661 663 661 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 775 777 775 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1110 1118 1110 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 b</xref>
###xml 1455 1463 1455 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 b</xref>
###xml 1535 1536 1535 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1538 1540 1538 1540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
###xml 1336 1340 <span type="species:ncbi:10090">mice</span>
The finding that under certain conditions recruitment of TEM cells in lymph nodes can be sustained for several weeks suggests the possibility that these cells might influence the DC maturation state through the constitutive expression of CD40L. To test this possibility, mice were transferred with Thy1.1+ OVA-specific DO11.10 naive T cells and primed with one or two consecutive s.c. injections of OVA-pulsed DCs (OVA-DC 1x and OVA-DC 2x, respectively) to generate TEM cells and to induce an acute or a chronic reactive lymph node (Fig. 5 a). Some mice were injected weekly with anti-CD62P blocking antibodies or isotype-matched control antibodies to inhibit TEM cell migration and the induction of chronic reactive lymph nodes. 30 d after priming, high numbers of DO11.10 TEM cells were recovered from chronic reactive but not acute reactive lymph nodes (Fig. S5, available at ). Interestingly, on day 30 after priming all DCs recovered from chronic reactive lymph nodes expressed increased levels of CD40 and MHC class II molecules as compared with DCs recovered from resting or acute reactive lymph nodes (Fig. 5 b). At this late time point, there was no evidence of persisting OVA antigen in reactive lymph nodes, as shown by the lack of proliferation of i.v.-injected CFSE-labeled OT-II T cells (unpublished data). Strikingly, in mice treated with blocking CD62P antibodies, DCs did not show increased expression of CD40 and MHC class II molecules (Fig. 5 b). These results are consistent with a role for lymph node-migrating CD4+ TEM cells in the induction of DC maturation in vivo.
###end p 31
###begin p 32
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T<sub>EM</sub> cells migrating into reactive lymph nodes maintain DCs in a mature immunostimulatory state.</bold>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 300 298 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 499 500 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 796 797 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1043 1044 1041 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1320 1321 1317 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1637 1639 1634 1636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1744 1745 1741 1742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1841 1843 1838 1840 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 135 139 <span type="species:ncbi:10090">Mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">Mice</span>
###xml 901 904 <span type="species:ncbi:31658">CFA</span>
###xml 955 959 <span type="species:ncbi:10090">mice</span>
###xml 1138 1142 <span type="species:ncbi:10090">mice</span>
###xml 1404 1408 <span type="species:ncbi:10090">mice</span>
###xml 1549 1553 <span type="species:ncbi:10090">mice</span>
TEM cells migrating into reactive lymph nodes maintain DCs in a mature immunostimulatory state. (a, d, and g) Experimental design. (a) Mice were transferred with Thy1.1+ DO11.10 OVA-specific T cells and either left untreated or primed with one or two s.c. injections of OVA-pulsed DCs to generate TEM cells and acute or chronic reactive lymph nodes. Some mice were injected weekly with 100 mug of control antibodies or anti-CD62P blocking antibodies. (b) Expression of CD40 and MHC class II on CD11c+ DCs purified 30 d after priming from resting (gray lines) or reactive (black lines) lymph nodes. (c) On day 30, mice were transferred with CFSE-labeled HA-specific 6.5 naive T cells and challenged with an i.v. injection of 10 mug HA in PBS. Shown are the percentages and the CFSE profiles of 6.5+ T cells in resting or reactive lymph nodes 5 d after challenge. (d) Mice received an s.c. injection of CFA to generate chronic reactive lymph nodes. Control mice received an s.c. injection of PBS. (e) Expression of CD40 and MHC class II on CD11c+ DCs purified 30 d after priming from resting or chronic reactive lymph nodes. (f) On day 30, mice were transferred with CFSE-labeled 6.5 naive T cells and challenged with an i.v. injection of 10 mug of HA protein in PBS. Shown are the percentages and the CFSE profiles of 6.5+ T cells in resting or chronic reactive lymph nodes 5 d after challenge. (g) Naive mice were adoptively transferred with CFSE-labeled 6.5 naive T cells, and a reactive lymph node was induced by s.c. injection of LPS. 5 d later, mice received an s.c. injection of HA in PBS together with an i.v. transfer of DO11.10 TEM cells that had been treated with control or CD40L-blocking antibodies. (h) Proliferative response of 6.5+ T cells in reactive lymph nodes in the absence or presence of untreated or anti-CD40L-treated TEM cells. Results are representative of two to five separate experiments.
###end p 32
###begin p 33
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 326 334 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 c</xref>
###xml 794 796 794 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 922 924 922 924 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 976 984 976 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 c</xref>
###xml 1153 1164 1153 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, d&#8211;f</xref>
###xml 1196 1198 1196 1198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 171 175 <span type="species:ncbi:10090">Mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1099 1102 <span type="species:ncbi:31658">CFA</span>
###xml 1183 1186 <span type="species:ncbi:31658">CFA</span>
We next asked whether TEM cell-matured DCs in chronic reactive lymph node would be capable of priming naive T cells to an antigen administered in the absence of adjuvant. Mice treated as above were adoptively transferred on day 30 with CFSE-labeled HA-specific 6.5 naive T cells and challenged by i.v. injection of HA in PBS (Fig. 5 c). As expected, no proliferative response was observed in control mice in response to HA administered in the absence of adjuvants. In addition, HA-specific T cells did not proliferate in mice in which a transient reactive lymph node was induced by a single injection of DCs (1x). In contrast, a strong proliferative response of HA-specific T cells was observed in chronic reactive lymph nodes induced by two injections of DCs (2x) and containing OVA-specific TEM cells. Strikingly, HA-specific T cells did not proliferate in mice chronically treated with CD62P antibodies, which blocked TEM cell migration into lymph nodes and DC maturation (Fig. 5 c and Fig. S5). Comparable results were obtained in mice in which a reactive lymph node was induced by injection of CFA and that did not receive DO11.10 T cell transfer (Fig. 5, d-f), suggesting that CFA-induced TEM cells emerging from the endogenous repertoire are sufficient to induce DC maturation and T cell priming.
###end p 33
###begin p 34
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 141 149 141 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 g</xref>
###xml 364 366 364 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 741 743 741 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 782 784 782 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 792 800 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 h</xref>
###xml 828 829 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 831 833 831 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 990 991 990 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 993 995 993 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 152 156 <span type="species:ncbi:10090">Mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
In another experimental set up, we measured the proliferative response of naive T cells in the presence of adoptively transferred TEM cells (Fig. 5 g). Mice transferred with CFSE-labeled HA-specific 6.5 naive T cells received a s.c. injection of LPS to induce a reactive lymph node. On day 5 after LPS injection, some mice were also transferred with OVA-specific TEM cells, which had been either untreated or treated with anti-CD40L antibodies and then challenged i.v. with HA in PBS. HA-specific T cells failed to proliferate in LPS-treated mice, consistent with our preliminary observation that the adjuvant effect of LPS is rapidly lost in vivo (unpublished data). In contrast, HA-specific T cells proliferated in lymph nodes containing TEM cells but not CD40L antibody-treated TEM cells (Fig. 5 h). Of note, treatment of CD4+ TEM cells with anti-CD40L antibodies did not prevent their migration into reactive lymph nodes (unpublished data). Collectively, these results indicate that CD4+ TEM cells migrating into chronic reactive lymph nodes act as an antigen-nonspecific endogenous adjuvant by continuously triggering DC maturation in a CD40L-dependent fashion and facilitating T cell immune responses to otherwise nonimmunogenic antigens.
###end p 34
###begin title 35
Induction of EAE in reactive lymph nodes in the absence of adjuvants
###end title 35
###begin p 36
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 115 113 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 302 305 <span type="species:ncbi:31658">CFA</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 485 488 <span type="species:ncbi:31658">CFA</span>
The findings described in the previous section raise the possibility that in chronic reactive lymph nodes, CD4+ TEM cells may license DCs for priming of autoreactive T cells. To test this possibility, we induced reactive lymph nodes by two consecutive injections of mature DCs or a single injection of CFA, and 1 mo later challenged the mice by s.c. injection of MOG peptides in PBS at sites draining into the reactive lymph node. Control mice were injected with MOG peptide in PBS or CFA. The clinical score of EAE was recorded in a blinded fashion by two researchers. In addition, brains and spinal cords were collected at the end of the experiments and analyzed for the presence of infiltrating CD4+ T cells.
###end p 36
###begin p 37
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 254 269 254 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, a and b</xref>
###xml 599 614 599 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, c and d</xref>
###xml 741 749 741 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 a</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1048 1063 1048 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, c and d</xref>
###xml 1131 1132 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1134 1136 1134 1136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 28 31 <span type="species:ncbi:31658">CFA</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 402 405 <span type="species:ncbi:31658">CFA</span>
###xml 594 597 <span type="species:ncbi:31658">CFA</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
###xml 736 739 <span type="species:ncbi:31658">CFA</span>
Injection of MOG peptide in CFA led to rapid development of clinical symptoms of EAE and to accumulation of CD4+ T cells in the central nervous system, whereas injection of MOG peptide in PBS did not result in any clinical symptoms or T cell infiltrate (Fig. 6, a and b). Remarkably, injection of MOG peptide in PBS in mice carrying a reactive lymph node, which had been induced by injection of either CFA or mature DCs 1 mo earlier, led to the development of clinical symptoms and T cell infiltrates that were comparable in severity and extent to those induced by the administration of MOG in CFA (Fig. 6, c and d). Pretreatment of mice with anti-CD62P antibodies did not interfere with EAE induced by immunization with MOG peptide in CFA (Fig. 6 a), consistent with the fact that CD62P is not required for migration of effector T cells into the brain (29). Remarkably, however, anti-CD62P treatment prevented EAE and T cell infiltration in the central nervous system induced by injection of MOG peptide in PBS draining into reactive lymph nodes (Fig. 6, c and d). Collectively, these data are consistent with a model in which CD4+ TEM cells recruited into reactive lymph nodes provide a licensing signal to resident DCs that facilitates response to self-antigens and the development of pathogenic autoreactive T cells.
###end p 37
###begin p 38
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EAE can be induced by presentation of MOG peptides in reactive lymph nodes and is inhibited by CD62P blockade.</bold>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 364 369 363 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35-55</sub>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 218 221 <span type="species:ncbi:31658">CFA</span>
###xml 381 384 <span type="species:ncbi:31658">CFA</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 620 624 <span type="species:ncbi:10090">Mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 860 864 <span type="species:ncbi:10090">mice</span>
EAE can be induced by presentation of MOG peptides in reactive lymph nodes and is inhibited by CD62P blockade. Groups of mice (n = 16), either untreated (a and b) or that had received 30 d earlier an s.c. injection of CFA or two consecutive s.c. injections of LPS-matured DCs to induce a chronic reactive lymph node (c and d), were challenged i.v. with 100 mug MOG35-55 peptide in CFA (a) or in PBS (b-d). For each experimental group, half of the mice received once a week an i.v. injection of 100 mug CD62P antibodies (circles) or isotype matched control antibodies (squares) for the entire duration of the experiment. Mice were graded daily for clinical manifestation of EAE. Shown are mean clinical scores of eight mice per group. Error bars represent the SE for each point. (right) CD4 expression on lymphocytes isolated from the brain and spinal cords of mice 20 d after priming with MOG peptide. Numbers are the percentage of the gated population. Results are representative of two separate experiments.
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
We have shown that CD4+ TEM cells, which migrate with low efficiency into resting lymph nodes, migrate in a CD62P-dependent fashion into reactive lymph nodes that have been induced to express, in a transient or sustained manner, CD62P on HEVs. In reactive lymph nodes, CD4+ TEM cells trigger maturation of DCs in an antigen-independent fashion via constitutively expressed CD40L and license them for T cell priming against antigens, including self-antigens, administered in the absence of exogenous adjuvants.
###end p 40
###begin p 41
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 156 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 247 249 247 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 525 526 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 691 692 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 694 696 694 696 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 890 891 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 893 895 893 895 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 981 982 981 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 984 986 984 986 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1138 1139 1138 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1141 1143 1141 1143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1381 1382 1381 1382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1384 1386 1384 1386 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1418 1420 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
We previously reported that, after s.c. injection of adjuvants or mature DCs, draining lymph nodes become capable of attracting leukocytes, such as CD8+ TEM and NK cells, that are largely excluded from resting lymph nodes (24, 25). Entry of CD8+ TEM and NK cells requires expression of CXCR3 on migrating cells and coincides with expression of the cognate chemokines on HEVs of reactive lymph nodes. Although the ligand for CD62P is expressed on CD8+ effector T cells, this adhesion molecule is not required for homing of CD8+ T cells to reactive lymph nodes, as demonstrated by experiments using specific blocking antibodies (unpublished data). The present study shows that migration of CD4+ TEM cells into reactive lymph nodes occurs through a different mechanism independent of CXCR3 and dependent on CD62P. This conclusion is based on the findings that wild-type and CXCR3-deficient CD4+ TEM cells showed a comparable capacity to migrate into reactive lymph nodes, and that CD4+ TEM cell migration was not observed in mice lacking CD62P/E and could be inhibited by antibodies against CD62P but not CD62E. In addition, migration of CD4+ TEM cells in lymph nodes coincides with expression of CD62P on HEVs that was induced, in an acute or chronic fashion, by adjuvants or mature DCs. Interestingly, chronic reactive lymph nodes did not appear to efficiently recruit cytotoxic CD8+ TEM cells as acute lymph nodes do (25), indicating that entry of these cells is restricted to the early phases of an immune response.
###end p 41
###begin p 42
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 208 206 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 875 876 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 878 880 874 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 980 982 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
A recent study demonstrated that antigen-primed lymph nodes contain a resident population of antigen-specific CXCR5+ICOS+ follicular helper T cells (30). In contrast to follicular helper T cells, the CD4+ TEM cells described in this paper continually recirculate through the reactive lymph nodes because they disappeared rapidly when entry was blocked by injection of CD62P antibodies. It remains to be established which lymphocyte integrin is involved in this process and whether chemokine-dependent activation of integrins is required, because the high amounts of LFA-1 and alpha4-integrins expressed on memory T cells may promote efficient adhesion of rolling cells even in the absence of chemokine signaling. In addition, one should consider the possibility that CD62P-expressing platelets adhering to HEVs may facilitate extravasation of P-selectin glycoprotein ligand 1+ TEM cells, as it has been suggested to allow for CD62P-dependent homing of CD62L-deficient leukocytes (31).
###end p 42
###begin p 43
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 455 457 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 459 461 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 575 577 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 753 754 750 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 756 758 753 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1279 1281 1276 1278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 556 561 <span type="species:ncbi:10090">mouse</span>
###xml 1044 1047 <span type="species:ncbi:31658">CFA</span>
###xml 1381 1384 <span type="species:ncbi:31658">CFA</span>
CD62P expression is known to be induced on the endothelial cells of inflamed peripheral tissues and to regulate recruitment of effector cells of the innate and adaptive immune system (32). Previous studies have shown that under conditions of intravital microscopy (but not in situ), CD62P can be expressed on HEVs of Peyer's patches and subiliac lymph nodes and can account for residual migration of leukocytes in the absence of CD62L or beta7-integrins (33, 34). CD62P was also reported to be expressed at low levels on HEVs in the course of experimental mouse listeriosis (35). Our results show for the first time that CD62P is induced in peripheral lymph node HEVs by s.c. injection of adjuvants or mature DCs and that it can mediate migration of CD4+ TEM cells. Intriguingly, CD62P expression on HEVs can be acute or chronic, depending on the nature of the eliciting stimuli. Although soluble TLR agonists (LPS, CpG, and R848) or a single injection of mature DCs induced a transient expression of CD62P (up to day 6), a single injection of CFA or two consecutive injections, 2 d apart, of mature DCs led to an up-regulation of CD62P that was sustained for >60 d. Importantly, the persistence of CD62P on HEVs correlates with increased lymph node cellularity, recruitment of TEM cells, and increased immunostimulatory capacity of lymph node-resident DCs. Although the effect of CFA may be explained by a sustained release of microbial products from a tissue depot, it remains to be established how two injections of mature DCs, which are known to be short lived, may induce a long-lasting change in the draining lymph node in the apparent absence of residual antigen, as shown by the finding that 30 d after injection of OVA-pulsed DCs, CFSE-labeled OVA-specific T cells failed to proliferate (unpublished data).
###end p 43
###begin p 44
###xml 255 258 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 417 419 411 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 644 646 638 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 980 982 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1205 1207 1199 1201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
We have provided evidence that T cells may be required for maintenance of chronic reactive lymph nodes. Indeed, although the initial increase of cell number in lymph nodes stimulated by adjuvants or mature DCs can be induced in T cell-deficient CD3epsilon-/- mice, the sustained increase in lymph node cellularity is dependent on the presence of T cells. The findings that antibodies to CD62P prevented migration of TEM cells and increased lymph node cellularity would be consistent with a role for these cells in the development of chronic reactive lymph nodes. However, at this point we cannot rule out the possibility that cells other than TEM cells requiring CD62P to enter lymph node might also be involved. In addition, it is possible that other changes besides sustained expression of CD62P may take place in reactive lymph nodes. For instance, innate stimuli have been shown to promote remodeling of the primary feed arteriole, leading to an increase in lymphocyte input (36). It is tempting to speculate that, once the inducing stimulus has reached a sufficient threshold, the reactive state of the lymph node may be maintained by irreversible structural changes or by continuous recruitment of TEM and/or innate immune cells.
###end p 44
###begin p 45
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 238 240 238 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 274 276 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 294 296 294 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 322 324 322 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 567 569 567 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 789 791 789 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 878 880 878 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 993 994 993 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 996 998 996 998 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1102 1104 1102 1104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1180 1182 1180 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1361 1363 1361 1363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1391 1393 1391 1393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1646 1648 1646 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1549 1554 <span type="species:ncbi:10090">mouse</span>
Another major finding of this study is that CD4+ TEM cells constitutively express CD40L at levels sufficient to trigger DC maturation and to license them for T cell priming (37). Constitutive CD40L expression was significantly higher in TEM cells as compared with naive or TCM cells, and only TEM cells, but not naive or TCM cells, triggered DC maturation and promoted T cell priming in vitro in an antigen-independent and CD40-dependent fashion. Importantly, this effect was also observed in vivo. DCs in chronic reactive lymph nodes, exposed to recirculating CD4+ TEM cells, homogeneously expressed high levels of MHC and co-stimulatory molecules and were able to trigger naive T cell proliferation in response to antigens administered in the absence of adjuvants. The critical role of TEM cells was demonstrated by the fact that injection of CD62P antibodies, which blocked TEM cell migration into reactive lymph nodes, inhibited both DC maturation and T cell priming. The efficiency of CD4+ TEM cells in inducing DC maturation may rely on the anatomy of the lymph node, which places extravasating TEM cells in direct contact with DCs, and on the high numbers and motility of TEM cells, and hence, their ability to interact with multiple DCs in a serial fashion (38). Although our results indicate that DC maturation and licensing is selectively induced by TEM cells but not by naive or TCM cells, we cannot rule out the possibility that constitutive expression of CD40L on the latter may contribute to DC survival and function. Indeed, CD40L on mouse naive T cells has been shown to be sufficient to promote survival of autoreactive B cells (19).
###end p 45
###begin p 46
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 294 296 294 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 685 687 685 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 870 872 870 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 990 992 990 992 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1154 1155 1154 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1157 1159 1157 1159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1401 1403 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1404 1406 1404 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 1541 1543 1541 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1545 1547 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 1576 1577 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1649 1650 1649 1650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1747 1749 1747 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 1751 1753 1751 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 2071 2073 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 1326 1330 <span type="species:ncbi:10090">mice</span>
###xml 1343 1348 <span type="species:ncbi:9606">human</span>
###xml 1367 1375 <span type="species:ncbi:9606">patients</span>
###xml 1845 1849 <span type="species:ncbi:10090">mice</span>
###xml 1872 1875 <span type="species:ncbi:31658">CFA</span>
Microbial products have been shown to be required to break tolerance to tissue antigens, leading to autoimmunity (39). In addition, LPS may activate autoreactive CD4+ cells in a bystander fashion (40). Based on our findings, we hypothesized that the DC licensing effect exerted by CD40L+ CD4+ TEM cells trafficking into reactive lymph nodes may facilitate immune responses to poorly immunogenic antigens, such as tissue antigens, in the apparent absence of microbial products. This possibility was demonstrated by the finding that EAE could be induced by injection of a MOG peptide at a site draining into the chronic reactive lymph node accessible to circulating antigen-nonspecific TEM cells. Although endogenous danger signals, such as ATP or uric acid (41), may play a synergistic role in the priming of autoreactive T cells, the finding that the mere exclusion of TEM cells form the reactive lymph nodes by CD62P antibody treatment was sufficient to prevent immunopathology points to TEM cells as the primary inducing factor in eliciting this pathogenic response. Although it is premature to envisage a role for CD40L constitutively expressed on CD4+ TEM cells in induction of autoimmune diseases, it is of note that increased levels of CD40L-expressing effector and memory T cells have been observed in autoimmune-prone mice (17) and in human memory T cells of patients with multiple sclerosis (42-44), and targeting the CD40-CD40L interaction has been proposed as a treatment for autoimmune diseases or to induce allograft tolerance (45, 46). In addition, activated CD4+ T cells have been shown to prime and expand endogenous autoreactive CD8+ T cells in an antigen-dependent or -independent fashion through the licensing of DCs via CD40L (47, 48). We found that clinical symptoms and the extent of T cell infiltration were comparable in mice immunized with MOG in CFA or with soluble MOG draining into a reactive lymph node. It remains to be established whether these distinctive priming environments generate a comparable spectrum of polarized effector T cells (49).
###end p 46
###begin p 47
In conclusion, our study provides evidence for a mechanistic link between changes in cell traffic in lymph nodes and predisposition to mount effector responses to otherwise nonimmunogenic antigens. We are currently testing the possibility that induction of chronic reactive lymph nodes at sites that drain tumor antigens may facilitate priming of effector T cells against the tumor.
###end p 47
###begin title 48
MATERIALS AND METHODS
###end title 48
###begin title 49
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 49
###begin p 50
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 589 590 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 763 764 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 853 856 853 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 931 934 931 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 1089 1092 1089 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 476 491 <span type="species:ncbi:10090">transgenic mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 586 590 <span type="species:ncbi:10090">H-2b</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">H-2b</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 1040 1055 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1105 1109 <span type="species:ncbi:10090">Mice</span>
C57BL/6 (H-2b) and BALB/c (H-2d) mice were purchased from Harlan. Transgenic DO11.10-Thy1.2 (H-2d) mice were purchased from Taconic. BALB/c-Thy1.1 mice, a gift of S.L. Swain (The Trudeau Institute, Saranac Lake, NY), were bred onto DO11.10-Thy1.2 mice in the animal facility of the Institute for Research in Biomedicine. Transgenic OT-II (H-2b) (50) and HA-TCR (H2d) (51) mice were obtained from J. Kirberg (Max-Plank-Institute of Immunobiology, Freiburg, Germany). The OT-II transgenic mice were also bred onto backgrounds of different CD45 alleles. CD62P/CD62E double-deficient mice (H-2b) were a gift of R.O. Hynes (Massachusetts Institute of Technology, Boston, MA) through B. Engelhardt (Theodor Kocher Institute, Bern, Switzerland). CD40-deficient mice (H-2b) (52) were obtained from K. Schwarz (Cytos Biotechnology AG, Zurich, Switzerland). CXCR3-/- mice were provided by C. Gerard (Harvard Medical School, Boston, MA). CD3e-/- mice (53) were obtained from B. Malissen (Centre d'Immunologie Marseille-Luminy, Marseille, France). All transgenic mice used in this study were on a Rag2-/- background. Mice were treated in accordance with the Swiss Federal Veterinary Office guidelines, and approval for animal experiments was obtained by the committee of the same office.
###end p 50
###begin title 51
DCs and cell transfer.
###end title 51
###begin p 52
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 819 824 <span type="species:ncbi:10090">mouse</span>
BM-derived DCs were generated as previously described (54) by culturing BM precursors from femurs of mice in RPMI 1640 medium supplemented with 10% (vol/vol) FCS, 1% (vol/vol) Glutamax, 1% (vol/vol) nonessential amino acids, 1% (vol/vol) pyruvate, 50 U/ml penicillin, 50 mug/ml streptomycin (all from Invitrogen), and 50 mug/ml 2-mercaptoethanol (Merck) in the presence of recombinant GM-CSF (R&D Systems). DC maturation was induced by overnight incubation with 0.5 mug/ml LPS (Sigma-Aldrich). Whole spleen cells were labeled with 0.3 or 2.5 muM CFSE (Invitrogen) or with 10 muM 5- and 6-(4-chloromethyl)benzoyl-amino-tetramethylrhodamine (Invitrogen). For in vivo blocking experiments, purified anti-CD62L, anti-CD62P, anti-CD62E, or isotype control antibodies (all from BD Biosciences) were injected i.v (100 mug per mouse). These experiments were performed either before or after transfer of fluorescently labeled cells and before or after injection of DCs, as indicated in the figures.
###end p 52
###begin title 53
Immunization.
###end title 53
###begin p 54
###xml 231 238 231 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">323-339</sub>
###xml 262 269 262 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">110-119</sub>
###xml 291 296 291 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35-55</sub>
###xml 657 658 655 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 879 880 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 892 893 890 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 981 982 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1138 1139 1135 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1202 1203 1199 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1326 1328 1323 1325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1334 1338 1331 1335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1343 1344 1340 1341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1349 1350 1346 1347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1353 1355 1350 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1361 1365 1358 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">high</sup>
###xml 1370 1371 1367 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1376 1377 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1399 1402 1396 1399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low</sup>
###xml 1407 1408 1404 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1413 1414 1410 1411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1450 1453 1447 1450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1471 1472 1468 1469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1483 1485 1480 1482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1492 1494 1489 1491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 1680 1684 1677 1681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1826</sub>
###xml 494 497 <span type="species:ncbi:31658">CFA</span>
###xml 1053 1057 <span type="species:ncbi:10090">mice</span>
###xml 1462 1466 <span type="species:ncbi:10090">mice</span>
###xml 1763 1766 <span type="species:ncbi:31658">CFA</span>
The following proteins and peptides were used: whole OVA protein was obtained from Sigma-Aldrich and KLH was obtained from EMD; purified HA of influenza A/IVR116 (H1N1) virus was a gift of G. Galli (Novartis, Siena, Italy); and OVA323-339 (ISQAVHAAHAEINEAGR), HA110-119 (SFERFEIFPK), and MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) peptides were synthesized by the Servei de Proteomica (Pompeu Fabra University, Barcelona, Spain). For immunization with adjuvant, 50 mug of whole protein was emulsified in CFA (DIFCO) and injected s.c. in the flank. Where indicated in the figures, immunization was performed i.v. with 10 mug OVA or HA in PBS. 3-4 wk after priming, CD4+ T cells were enriched from spleen and peripheral lymph nodes with CD4 magnetic beads (Miltenyi Biotec) and sorted using a FACSAria (BD Biosciences) according to the expression of CD44, CD62L, and CD127. Transgenic Thy1.1+ DO11.10 CD4+ T cells were purified from spleen and lymph nodes and labeled with 2.5 muM CFSE, and 106 cells were injected i.v. into syngeneic hosts. Adoptively transferred mice received one (DC 1x) or two consecutive (2 d apart; DC 2x) s.c. injections of 106 OVA-loaded, LPS-matured DCs. 3-4 wk after priming, DO11.10 CD4+ T cells were enriched from spleen and lymph nodes by cell sorting according to the expression of CD44, CD62L, and CD127 (TCM, CD44highCD62L+CD127+; TEM, CD44highCD62L-CD127+). Naive T cells (CD44lowCD62L+CD127+) were purified from spleens of Rag2-/- DO11.10 mice. CD4+ naive T, TCM, and TEM cells were adoptively transferred into syngeneic hosts or used in vitro, as indicated in the figures. Reactive lymph nodes were in some experiments induced by s.c. injection of LPS, CpG1826 oligodeoxynucleotide (5'-CCATGACGTTCCTGACGTT-3'; Microsynth), IFA (DIFCO), or CFA. Peritonitis was induced by an i.p. injection of a 3% solution (wt/vol) of thioglycolate (Sigma-Aldrich) in PBS.
###end p 54
###begin title 55
In vitro experiments.
###end title 55
###begin p 56
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 186 188 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 194 196 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 337 339 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 548 550 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 634 635 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 980 982 978 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 987 989 985 987 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 993 994 991 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1117 1118 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1122 1123 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1134 1136 1132 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 1143 1145 1141 1143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 524 529 <span type="species:ncbi:9606">human</span>
Naive antigen-specific CD4+ T cells were primed in vitro with immature or with LPS-matured DCs pulsed with the peptides indicated in the figures (T cell/DC ratio = 10:1). CD4+ naive T, TCM, or TEM cells specific for a different antigen were added to these cultures. Polyclonal and OT-II CD4+ T cells were primed in vivo, and 3 wk later TEM CD4+ T cells were sorted as before and expanded in vitro with 10 mug/ml each of anti-CD3 and anti-CD28 (both from BD Biosciences). On day 4, cultures were supplemented with 10 U/ml of human recombinant IL-2 (55), and cells were collected 7-9 d later. To measure surface expression of CD40L, CD4+ T cells were activated in vitro with soluble 10 mug/ml anti-CD3 (BD Biosciences) and 10 ng/ml phorbol-12,13 dibutyrate (PDBu; Sigma-Aldrich). At the time points after stimulation indicated in the figures, cold PBS containing 5% FCS was added to the cells. Immature BM-DCs were prepared and co-cultured in vitro with naive or in vivo-generated TCM or TEM CD4+ T cells. DCs were analyzed for expression of CD40, CD86, and MHC-II 12 h after co-culture. For fixation of T cells, 5 x 106 CD4+ naive T, TCM, and TEM cells were washed in PBS/1% FCS and fixed in 1 ml 0.05% glutaraldehyde (Merck) for 30 s at room temperature. 1 ml of 0.2 M Glycin (Sigma-Aldrich) was then added for 30 s. Cells were finally washed and co-cultured with immature DCs.
###end p 56
###begin title 57
Flow cytometry and cell sorting.
###end title 57
###begin p 58
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 877 878 873 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1064 1066 1060 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 331 336 <span type="species:ncbi:10090">mouse</span>
###xml 654 659 <span type="species:ncbi:10090">mouse</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 866 870 <span type="species:ncbi:9925">goat</span>
###xml 884 889 <span type="species:ncbi:9606">human</span>
The following monoclonal antibodies were used: anti-CD62L (MEL14), anti-CD62P (RB40.34), anti-CD62E (10E9.6), anti-CD44 (IM7), anti-CD4 (L3T4), anti-CD8 (Ly-2), anti-CD3 (145-2C11), anti-CD11c (HL3), anti-CD40 (3/23), anti-IA/IEd (2G9), anti-CD86 (PO3), anti-IFN-gamma (XMG1.2), anti-IL-2 (JES6-5H4), anti-TNF (MP6-XT22), and anti-mouse DO11.10 clonotypic TCR (KJ1-26; all from BD Biosciences). The anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD90.1 (HIS51), anti-CD127 (A7R34), and anti-CCR7 (4B12) antibodies were from eBioscience. The anti-CXCR3 (220803) antibody was from R&D Systems. The anti-CD154 (MR-1) antibody was from SouthernBiotech. The anti-mouse HA clonotypic TCR (clone 6.5) was a gift of J. Kirberg. CD62P ligands on T cells were detected by staining with a human IgG-CD62P fusion protein (BD Biosciences), followed by incubation with a biotinylated-goat F(ab')2 anti-human IgG antibody (SouthernBiotech) and streptavidin-allophycocyanin (APC; Invitrogen). Cytokine production was measured by intracellular staining after 4 h of stimulation with 10-7 M PMA and 1 mug/ml ionomycin (both from Sigma-Aldrich), with the last 2 h of culture in the presence of 10 mug/ml brefeldin A (Sigma-Aldrich). APC-labeled antibodies to IFN-gamma, IL-2, and TNF (BD Bioscience) were used after cell fixation in 4% (wt/vol) paraformaldehyde and permeabilization with 0.5% (wt/vol) saponin (Sigma-Aldrich). 6-color staining of the cell surface was done with the appropriate combinations of antibodies conjugated to FITC, PE, PerCP, PE-Cy7, APC, APC-Cy7, or biotin, and with streptavidin labeled with PE-Cy7 or APC-Cy7 (BD Biosciences). Samples were acquired on a FACSCanto (BD Biosciences) and were analyzed with FlowJo software (Tree Star, Inc.).
###end p 58
###begin title 59
Immunohistochemistry and histology.
###end title 59
###begin p 60
###xml 238 243 <span type="species:ncbi:10090">mouse</span>
###xml 679 682 <span type="species:ncbi:10116">rat</span>
###xml 766 772 <span type="species:ncbi:9793">donkey</span>
###xml 778 781 <span type="species:ncbi:10116">rat</span>
For detection of CD62P, reactive lymph nodes were induced by s.c. injection of LPS-matured DCs or adjuvant, as indicated in the figures. In some experiments, 50 mug of FITC-labeled anti-CD62P or anti-CD62E antibodies (BD Biosciences) per mouse were injected i.v. 30 min after antibody treatment. Draining reactive and control resting lymph nodes were collected and snap frozen in liquid nitrogen. Tissue sections of 6-mum thickness were prepared and directly processed for microscopic visualization without further counterstaining. For PNAd detection, tissue sections were fixed in cold (4degreesC) acetone for 10 min and incubated for 30 min with a 1:100 dilution of PE-labeled rat IgM MECA-79 antibody (BD Biosciences), followed by incubation with Alexa Fluor 594 donkey anti-rat IgM (Invitrogen). A microscope (Eclipse E800; Nikon) was used for immunofluorescence analysis. Separate images were collected for each fluorochrome, and images were overlaid to produce a multicolor image with Openlab 5 software (Improvision). Individual images were juxtaposed with Photoshop software (Adobe) to reconstitute the image of lymph node cross sections.
###end p 60
###begin title 61
EAE.
###end title 61
###begin p 62
###xml 139 144 138 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35-55</sub>
###xml 348 353 346 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35-55</sub>
###xml 1300 1301 1290 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 57 60 <span type="species:ncbi:31658">CFA</span>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 376 379 <span type="species:ncbi:31658">CFA</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">Mice</span>
Groups of 6-wk-old C57BL/6 mice were immunized s.c. with CFA in PBS (50:50, vol/vol). 30 d later mice were challenged i.v. with 100 mum MOG35-55 peptide in PBS containing 200 ng pertussis toxin (PTX; Sigma-Aldrich). A second injection of PTX was given 2 d later. Control 8-10-wk-old C57BL/6 female mice were immunized s.c. on day 0 with 100 mug MOG35-55 peptide emulsified in CFA. PTX was injected i.v. twice in 100 mul saline, on days 0 and 2. Groups of mice received 100 mum anti-CD62P antibodies or isotype-matched irrelevant antibodies as controls once a week. Control mice received IFA alone. Mice were graded for clinical manifestation of EAE on a 0-5 scale in a blinded manner. A 5-point disease severity scale was used, as follows: 0, no disease; 1, tail weakness; 2, paraparesis; 3, paraplegia; 4, paraplegia with forelimb weakness or paralysis; and 5, moribund or dead animal. For the isolation of lymphocytes infiltrating the central nervous system, brains and spinal cords were excised and dissociated for 1 h at 37degreesC in 1 mg/ml collagenase D (Roche) in RPMI 1640 medium. Cells were passed through a nylon mesh, pelleted, and resuspended in RPMI 1640 medium, and layered onto a Lympholyte-M density gradient (Cedarlane). Tubes were centrifuged at room temperature for 20 min at 800 g. Viable lymphocytes were removed from the interface.
###end p 62
###begin title 63
Statistical analysis.
###end title 63
###begin p 64
###xml 71 72 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Data, presented as means +/- SD, were analyzed with a paired Student's t test using the SPSS software (v16). P < 0.05 was considered significant.
###end p 64
###begin title 65
Online supplemental material.
###end title 65
###begin p 66
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">CM</sub>
###xml 58 60 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 204 206 204 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 315 317 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 524 526 524 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">EM</sub>
###xml 586 592 586 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
Fig. S1 shows the sorting strategy for T naive, TCM, and TEM cells. Fig. S2 shows that adoptively transferred naive T and TEM cells localized in the same area in reactive lymph nodes. Fig. S3 shows that TEM cell migration into the reactive lymph node is not dependent on the presence of specific antigen, and that TEM cells do not represent a resident population in reactive lymph nodes. Fig. S4 shows that T cells may be required for induction of chronic reactive lymph nodes. Fig. S5 shows the absolute number of DO11.10 TEM cells in chronic reactive lymph nodes in the experiment in Fig. 5.
###end p 66
###begin title 67
Supplementary Material
###end title 67
###begin title 68
[Supplemental Material Index]
###end title 68
###begin p 69
###xml 114 118 <span type="species:ncbi:10090">mice</span>
We thank J. Kirberg, S.L. Swain, R.O. Hynes, K. Schwarz, B. Engelhardt, and C. Gerard for transgenic and knockout mice; J. Stein for critical reading and discussions; D. Jarrossay, E. Mira-Cato, and L. Perlini for technical help; and K. Kuscher for help in manuscript editing.
###end p 69
###begin p 70
Supported by the Swiss National Science Foundation (grants 31-63885 and 31-109832 to F. Sallusto and A. Martin-Fontecha, respectively), the European Commission FP6 "Network of Excellence" initiative (grants LSHG-CT-2003-502935 MAIN, LSHB-CT-2004-512074 DC-THERA, and LSHG-CT-2005-005203 MUGEN), and the Helmut Horten Foundation (to the Institute for Research in Biomedicine). D. Baumjohann is the recipient of a Boehringer Ingelheim Fonds PhD Scholarship. A. Reboldi is supported by the European Union-funded International Graduate Program in Molecular Medicine.
###end p 70
###begin p 71
The authors declare no competing financial interests.
###end p 71

